Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results

被引：54

作者：

Ferrari F.S. ^{[1
]}

Megliola A. ^{[1
]}

Scorzelli A. ^{[1
]}

Stella A. ^{[2
]}

Vigni F. ^{[1
]}

Drudi F.M. ^{[3
]}

Venezia D. ^{[1
]}

机构：

[1] Department of Radiology, Siena University, Policlinico Santa Maria

[2] Departement of Oncology, Siena University, Policlinico Santa Maria, I-53100 Siena

[3] Department of Radiology, University La Sapienza, I-00161 Rome

来源：

La radiologia medica | 2007年 / 112卷 / 3期

关键词：

Hepatocellular carcinoma; Laser ablation; Radiofrequency ablation (RFA);

D O I：

10.1007/s11547-007-0148-2

中图分类号：

学科分类号：

摘要：

Purpose. The aim of this trial was to compare the results obtained using laser ablation (LA) and radiofrequency ablation (RFA) to treat small hepatocellular carcinomas (HCC). Materials and methods. From 2003 to 2005, a total of 81 cirrhotic patients (59 Child-Pugh A, 22 Child-Pugh B) presenting a total of 95 HCC nodules (mean diameter 27.9 mm) were treated with LA (41) and RFA (40). Results. Computed tomography (CT) revealed complete tumour ablation in 78% of nodules treated with LA and in 94% of those treated with RA; the disease-free interval was 16.50±8.1 months. The cumulative survival rates were 91.8%, 59% and 28.4% at 12, 36 and 60 months, respectively. The patients treated with RFA had better survival rates than those treated with LA, although this difference was not statistically significant (p=0.3299). Univariate analysis of survival revealed statistically significant differences between the Child-Pugh A and B groups (p<0.0001), between HCC nodules measuring ≤25 mm and >25 mm (p=0.0001) and between patients with a single nodule and with two nodules (p=0.0484). Conclusions. We found LA and RFA to be equally effective. However, RA appears more suited to patients with small HCC nodules and in Child-Pugh class A. © 2007 Springer-Verlag Italia.

引用

页码：377 / 393

页数：16

共 23 条

[1]

Colombo M., Sangiovanni A., Etiology, natural history and treatment of hepatocellular carcinoma, Antiviral Res, 60, pp. 145-150, (2003)

[2]

Parkin D.M., Bray F., Ferlay J., Pisani P., Estimating the world cancer burden: Globocan 2000, Int J Cancer, 94, pp. 153-156, (2001)

[3]

Colombo M., de Franchis R., Del Ninno E., Et al., Hepatocellular carcinoma in italian patients with cirrhosis, N Engl J Med, 325, pp. 675-680, (1991)

[4]

Fattovich G., Stroffolini T., Zagni I., Donato F., Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterol, 127, SUPPL. 1, (2004)

[5]

Bolondi L., Screening for hepatocellular carcinoma in cirrhosis, J Hepatol, 39, pp. 1076-1084, (2003)

[6]

Head H.W., Dodd G.D., Thermal ablation for hepatocellular carcinoma, Gastroenterology, 127, SUPPL. 1, (2004)

[7]

Poon R.T., Fan S.T., Tsang F.H., Wong J., Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective, Ann Surg, 235, pp. 466-486, (2002)

[8]

Bruix J., Sherman M., Management of hepatocellular carcinoma, Hepatol, 42, pp. 1208-1236, (2005)

[9]

Goldberg S.N., Grassi C.J., Cardella J.F., Et al., Image-guided tumor ablation: Standardization of terminology and reporting criteria, J Vasc Interv Radiol, 16, pp. 765-778, (2005)

[10]

Livraghi T., Goldberg S.N., Lazzaroni S., Et al., Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection, Radiology, 210, pp. 655-661, (1999)

← 1 2 3 →